Meros Investment Management LP Invests $1.13 Million in Harvard Bioscience, Inc. $HBIO

Meros Investment Management LP bought a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned about 4.02% of Harvard Bioscience at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in Harvard Bioscience during the 4th quarter worth approximately $26,000. Legato Capital Management LLC grew its stake in Harvard Bioscience by 210.4% in the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 29,462 shares during the period. Jane Street Group LLC lifted its position in Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Harvard Bioscience by 291.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 37,057 shares in the last quarter. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Harvard Bioscience in the fourth quarter valued at $38,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HBIO has been the subject of several research reports. Weiss Ratings downgraded shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Benchmark boosted their price objective on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.75.

Harvard Bioscience Stock Performance

HBIO traded up $0.10 during trading on Friday, hitting $8.00. 17,397 shares of the company traded hands, compared to its average volume of 37,258. The company has a quick ratio of 0.98, a current ratio of 1.87 and a debt-to-equity ratio of 4.94. Harvard Bioscience, Inc. has a one year low of $3.75 and a one year high of $9.40. The firm has a market cap of $36.42 million, a P/E ratio of -3.46 and a beta of 1.49. The stock’s fifty day moving average is $6.38 and its 200 day moving average is $5.97.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. The company had revenue of $22.73 million for the quarter, compared to the consensus estimate of $21.45 million.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.